Vimarsana
Biggest News Aggregation in the World

Page 2 - Auto Injectors News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Auto Injectors. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Auto Injectors Today - Breaking & Trending Today

Auto-Injectors Market Key Players : Sanofi, Pfizer, Inc., Becton, Dickinson and Company, Mylan N.V., - Vimarsana News

Auto-Injectors Market Key Players : Sanofi, Pfizer, Inc., Becton, Dickinson and Company, Mylan N.V.,

Anaphylactic shock is the most common chronic disease in Europe and North America region. Allergy UK says, approximately 20% of patients struggle with anaphylactic reaction in Europe. Anaphylactic shock requires adrenaline auto injector devices to be treated. Adrenaline auto injectors are sold under various brands,...

Needle-Free Epinephrine Options Are On The Horizon - Vimarsana News

Needle-Free Epinephrine Options Are On The Horizon

Epinephrine is the only effective treatment for serious allergic reactions called anaphylaxis, yet people with prescriptions for the lifesaving medication often don't carry their auto-injectors, and many hesitate to use them.

Source: webmd.com
Lessons the Covid-19 pandemic taught about delivering essential vaccines - Vimarsana News

Lessons the Covid-19 pandemic taught about delivering essential vaccines

From the value of collaboration to the need to plan ahead, pharma can learn from the pandemic when it comes to supplying other essential vaccines.

Covid-19 update: More than 5 million children orphaned by Covid-19 - Vimarsana News

Covid-19 update: More than 5 million children orphaned by Covid-19

At least 5.2 million children have lost a parent or caregiver to Covid, putting them at risk of poverty, exploitation and abuse.

MGH and BWH identify multi-inflammatory syndrome drug for children - Vimarsana News

MGH and BWH identify multi-inflammatory syndrome drug for children

Massachusetts General Hospital (MGH) and BWH researchers have identified a drug candidate, larazotide acetate, to treat MIS-C in children.